How do you reconcile the lack of OS benefit in the CLEAR trial comparing Lenvatinib + Pembrolizumab to Sunitinib, to the very impressive ORR and mPFS benefit seen?

mOS was 53.7 in experimental v. 54.3 in control; however ORR 71.3% vs. 36.7%, and mPFS 23.9 mo vs. 7.2 mo (HR 0.47). Does the lack of OS benefit sway you to other IO+TKI or IO+IO regimens in 1L aRCC?

Answer from: Medical Oncologist at Community Practice

At the primary analysis point of the phase III open-label, CLEAR study (Study 307/KEYNOTE-581), with a median survival follow-up of 26.6 months, lenvatinib plus pembrolizumab showed superior efficacy versus sunitinib in the first-line treatment of patients with advanced renal cell carcinoma. (Motzer...

Please select the option that best describes you:

How do you reconcile the lack of OS benefit in the CLEAR trial comparing Lenvatinib + Pembrolizumab to Sunitinib, to the very impressive ORR and mPFS benefit seen?

Related Questions